Autoimmune blistering diseases: Promising agents in clinical trials.

Henning OlbrichChristian D SadikEnno Schmidt

Published in: Expert opinion on investigational drugs (2023)

Promising results were shown for a variety of new agents including nomacopan, efgartigimod, omalizumab, dupilumab, as well as chimeric autoantibody receptor T cells. Clinical translation in the field of AIBDs is highly active and we anticipate significant advances in the treatment landscape.

Keyphrases

clinical trial
cell therapy
multiple sclerosis
atopic dermatitis
single cell
stem cells
randomized controlled trial
bone marrow
drug induced
phase iii
smoking cessation